Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in Refractory mCRC With APC, TP53, and RAS Mutations
NCT04853043Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Nov 2021
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140, sponsored by University of Utah. Started Nov 2021; status: terminated.
02
Drugs
KL-140
Beyond the preview
Go deeper on NCT04853043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853043.